Cold Allergy And Sinus Tablet Global Market Report 2025

Cold allergy and sinus tablets are over-the-counter or prescription medications formulated to relieve symptoms related to colds, allergies, and sinus conditions. These tablets typically combine antihistamines, decongestants, and pain relievers to reduce inflammation, congestion, and discomfort caused by these conditions.

The main types of cold allergy and sinus tablets include antihistamines, decongestants, cough suppressants, expectorants, and combination tablets. Antihistamines are medications that block or reduce the effects of histamines, chemicals released by the immune system during allergic reactions. These products are available in various formulations, including tablets, capsules, liquids, effervescent tablets, and powders. The consumer age groups vary from children (0-12 years) to teenagers (13-19 years), adults (20-64 years), and seniors (65 years and above). These products address multiple conditions, such as allergic rhinitis, the common cold, sinusitis, and more. Distribution occurs through several channels, including pharmacies, online stores, supermarkets or hypermarkets, and others.

The cold allergy and sinus tablet market research report is one of a series of new reports that provides cold allergy and sinus tablet market statistics, including the cold allergy and sinus tablet industry global market size, regional shares, competitors with the cold allergy and sinus tablet market share, detailed cold allergy and sinus tablet market segments, market trends, and opportunities, and any further data you may need to thrive in the cold allergy and sinus tablet industry. This cold allergy and sinus tablet market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenarios of the industry.

Coil transcatheter embolization and occlusion devices are minimally invasive medical devices designed to block (embolize) blood flow in a vessel or abnormal vascular structure. These devices are typically small metal coils that are delivered via a catheter through the vascular system to the target site.

The product types of coil transcatheter embolization and occlusion devices include detachable coils, pushable coils, and others. Detachable coils are implantable devices used in minimally invasive procedures to block blood flow in aneurysms or abnormal blood vessels, allowing for precise placement through a catheter once the target site is confirmed. These devices are applied in various procedures, including hemorrhage control, vascular occlusion, aneurysm treatment, tumor embolization, and others. They are made from materials such as platinum or platinum alloys, nickel titanium (nitinol), stainless steel, and others. Key end users of these devices include hospitals, ambulatory surgical centers (ASCs), specialty clinics, and research and academic institutions.

The coil transcatheter embolization and occlusion devices market research report is one of a series of new reports that provides coil transcatheter embolization and occlusion devices market statistics, including the coil transcatheter embolization and occlusion devices industry's global market size, regional shares, competitors with the coil transcatheter embolization and occlusion devices market share, detailed coil transcatheter embolization and occlusion devices market segments, market trends and opportunities, and any further data you may need to thrive in the coil transcatheter embolization and occlusion devices market. This coil transcatheter embolization and occlusion devices market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenarios of the industry.

The coil transcatheter embolization and occlusion devices market size has grown strongly in recent years. It will grow from $1.64 billion in 2024 to $1.78 billion in 2025 at a compound annual growth rate (CAGR) of 8%. The growth during the historic period can be attributed to factors such as the growing demand for image-guided procedures, expanding applications in trauma care, increased investments in interventional radiology, the rising use of embolization in gastrointestinal bleeding management, and the growing approvals of novel coil designs.

The coil transcatheter embolization and occlusion devices market size is expected to see strong growth in the next few years. It will grow to $2.4 billion in 2029 at a compound annual growth rate (CAGR) of 7.8%. The projected growth during the forecast period is driven by factors including the increasing prevalence of aneurysms, a rising adoption of minimally invasive procedures, a growing geriatric population, an increasing incidence of cancer, and rising healthcare expenditure. Key trends in the forecast period include advancements in detachable coil technology, the integration of microcatheters with enhanced flexibility, technological developments in imaging guidance systems, advancements in bioactive and coated coil materials, and the integration of real-time 3D imaging.

The cold allergy and sinus tablet market size has grown strongly in recent years. It will grow from $29.0 billion in 2024 to $30.64 billion in 2025 at a compound annual growth rate (CAGR) of 5.6%. The growth during the historic period can be attributed to the increasing prevalence of seasonal allergies, a rise in over-the-counter (OTC) medication sales, greater awareness of allergy symptoms, a rise in sinus infections, and improved healthcare access in developing countries.

The cold allergy and sinus tablet market size is expected to see strong growth in the next few years. It will grow to $37.69 billion in 2029 at a compound annual growth rate (CAGR) of 5.3%. Growth during the forecast period is expected to be driven by higher levels of air pollution, increased urbanization, a growing elderly population, rising demand for non-drowsy formulations, and an uptick in respiratory illnesses. Key trends anticipated for the forecast period include a shift toward natural and herbal remedies, a growing preference for combination therapies, personalized allergy treatments, innovations in nasal drug delivery systems, and an emphasis on pediatric-friendly formulations.

The increasing incidence of allergies and respiratory disorders is projected to drive growth in the cold allergy and sinus tablet market in the years ahead. These conditions involve immune system responses to allergens and affect the respiratory system, leading to illnesses such as asthma and allergic rhinitis. The surge in allergies and respiratory issues is largely linked to rising air pollution, which heightens exposure to allergens and airborne irritants that trigger adverse immune and respiratory reactions. Cold allergy and sinus tablets assist in managing these conditions by providing effective symptom relief, thereby enhancing the quality of life for individuals suffering from colds, sinus infections, and allergic reactions. For example, in September 2023, the World Health Organization, an intergovernmental agency based in Switzerland, reported that chronic respiratory diseases were responsible for 4.1 million deaths, ranking behind cardiovascular disease (17.9 million deaths) and cancer (9.3 million deaths), and ahead of diabetes (2 million deaths). Thus, the rising prevalence of respiratory and allergic conditions is fueling demand in the cold allergy and sinus tablet market.

Key players in the cold allergy and sinus tablet sector are investing in advanced drug formulations, such as extended-release tablets, to provide prolonged symptom relief and greater convenience for users. Extended-release tablets are designed to gradually deliver medication over an extended timeframe, ensuring sustained therapeutic effects. For instance, in July 2022, Dr. Reddy’s Laboratories Ltd., a pharmaceutical firm based in India, launched an over-the-counter (OTC) store-brand version of Allegra-D 24 HR in the United States. This formulation combines 180 mg of Fexofenadine HCl with 240 mg of Pseudoephedrine HCl in an extended-release format, offering 24-hour relief from sinus pressure, nasal congestion, and sneezing. The product delivers a cost-effective, non-drowsy alternative for managing symptoms associated with seasonal allergic rhinitis and similar conditions.

In June 2022, Glenmark Pharmaceuticals Ltd., an India-based drug manufacturer, acquired approved generic versions of several OTC medications from Wockhardt Ltd. for an undisclosed sum. This move was intended to strengthen Glenmark’s foothold in the U.S. OTC market by broadening its range of approved generic offerings, enhancing its market presence, and improving access for consumers. Wockhardt Ltd. is also based in India and produces a variety of cold, allergy, and sinus treatment products.

The increasing incidence of allergies and respiratory disorders is projected to drive growth in the cold allergy and sinus tablet market in the years ahead. These conditions involve immune system responses to allergens and affect the respiratory system, leading to illnesses such as asthma and allergic rhinitis. The surge in allergies and respiratory issues is largely linked to rising air pollution, which heightens exposure to allergens and airborne irritants that trigger adverse immune and respiratory reactions. Cold allergy and sinus tablets assist in managing these conditions by providing effective symptom relief, thereby enhancing the quality of life for individuals suffering from colds, sinus infections, and allergic reactions. For example, in September 2023, the World Health Organization, an intergovernmental agency based in Switzerland, reported that chronic respiratory diseases were responsible for 4.1 million deaths, ranking behind cardiovascular disease (17.9 million deaths) and cancer (9.3 million deaths), and ahead of diabetes (2 million deaths). Thus, the rising prevalence of respiratory and allergic conditions is fueling demand in the cold allergy and sinus tablet market.

Key players in the cold allergy and sinus tablet sector are investing in advanced drug formulations, such as extended-release tablets, to provide prolonged symptom relief and greater convenience for users. Extended-release tablets are designed to gradually deliver medication over an extended timeframe, ensuring sustained therapeutic effects. For instance, in July 2022, Dr. Reddy’s Laboratories Ltd., a pharmaceutical firm based in India, launched an over-the-counter (OTC) store-brand version of Allegra-D 24 HR in the United States. This formulation combines 180 mg of Fexofenadine HCl with 240 mg of Pseudoephedrine HCl in an extended-release format, offering 24-hour relief from sinus pressure, nasal congestion, and sneezing. The product delivers a cost-effective, non-drowsy alternative for managing symptoms associated with seasonal allergic rhinitis and similar conditions.

In June 2022, Glenmark Pharmaceuticals Ltd., an India-based drug manufacturer, acquired approved generic versions of several OTC medications from Wockhardt Ltd. for an undisclosed sum. This move was intended to strengthen Glenmark’s foothold in the U.S. OTC market by broadening its range of approved generic offerings, enhancing its market presence, and improving access for consumers. Wockhardt Ltd. is also based in India and produces a variety of cold, allergy, and sinus treatment products.

Major players in the cold allergy and sinus tablet market are Johnson & Johnson, Merck & Co. Inc., AbbVie Inc., Bayer AG, Sanofi S.A., Takeda Pharmaceutical Company Limited, GlaxoSmithKline plc, Reckitt Benckiser Group plc, Teva Pharmaceutical Industries Ltd., Mylan N.V., Sandoz Group AG, Alcon Inc., Sun Pharmaceutical Industries Ltd., Perrigo Company plc, Dr. Reddy's Laboratories, Cipla Limited, Hikma Pharmaceuticals plc, Lupin Ltd., Glenmark Pharmaceuticals Ltd., LETI Pharma GmbH.

North America was the largest region in the cold allergy and sinus tablet market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in cold allergy and sinus tablet report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East and Africa.

The countries covered in the cold allergy and sinus tablet market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

The cold allergy and sinus tablet market consists of sales of allerhin cold tablet, sinarest tablet, and allergix cold care tablet. Values in this market are ‘factory gate’ values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified).

The revenues for a specified geography are consumption values and are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

This product will be delivered within 3-5 business days.